

Review

# Distinguishing phospholipase A<sub>2</sub> types in biological samples by employing group-specific assays in the presence of inhibitors

Karin Killermann Lucas, Edward A. Dennis\*

*University of California, San Diego School of Medicine, Department of Chemistry, Biochemistry and Pharmacology, 9500 Gilman Drive, La Jolla, San Diego, CA 92093 0601, USA*

Received 14 February 2005; accepted 15 February 2005

Available online 10 May 2005

---

## Abstract

This manuscript reviews and updates radiolabel-based enzyme assays designed to distinguish the activity of phospholipase A<sub>2</sub> (PLA<sub>2</sub>) types in biological samples. This approach should be useful in lipidomics studies. The assays were originally designed to differentiate between Group IVA cytosolic PLA<sub>2</sub> (GIVA cPLA<sub>2</sub>), Group VIA calcium-independent PLA<sub>2</sub> (GVIA iPLA<sub>2</sub>), Group IIA secreted PLA<sub>2</sub> (GIIA sPLA<sub>2</sub>) and Group V secreted PLA<sub>2</sub> (GV sPLA<sub>2</sub>). The specificity of these assays has now been confirmed using purified, recombinant human PLA<sub>2</sub>s and the utility of these assays is demonstrated with rat spinal cord homogenate as an example of a biological tissue sample of interest to the neuroscience community. Modifications to the original assays by the addition of group-specific inhibitors are presented to ensure the specificity of the assays and to further differentiate between recently identified PLA<sub>2</sub>s. Specific tests are suggested to confirm the specificity of each assay. Additionally, it was discovered that one commonly used GIVA cPLA<sub>2</sub>/GVIA iPLA<sub>2</sub> inhibitor, methyl arachidonyl fluorophosphonate (MAFP) from one commercial source, was found to inhibit GIIA sPLA<sub>2</sub> and GV sPLA<sub>2</sub>, but not GIVA cPLA<sub>2</sub>, presumably due to oxidation of the compound during shipment, resulting in a different molecule with altered specificity.

© 2005 Elsevier Inc. All rights reserved.

**Keywords:** Lipidomics; Phospholipase A<sub>2</sub>; MAFP; BEL; Indoxam; Dole assay; PLA<sub>2</sub> activity assay; PIP<sub>2</sub>

---

\* Corresponding author. Tel.: +1 858 534 3055; fax: +1 858 534 7390.

*E-mail address:* edennis@ucsd.edu (E.A. Dennis).

## Contents

1. Introduction .....	236
2. Materials and methods .....	237
2.1. Materials .....	237
2.2. Phospholipase A <sub>2</sub> enzymes .....	237
2.3. Preparation of rat spinal cord homogenate and rat cerebral spinal fluid .....	238
2.4. Phospholipase A <sub>2</sub> assays .....	238
2.4.1. Lipid preparation .....	238
2.4.2. Assay conditions .....	238
2.4.3. Data analysis .....	239
3. Results and discussion .....	239
3.1. Group-specific assays on pure enzymes .....	239
3.2. Proof of principle: testing a biological sample .....	239
3.3. Specificity improved assays .....	242
3.3.1. GIVA cPLA <sub>2</sub> .....	242
3.3.2. GVI iPLA <sub>2</sub> .....	243
3.3.3. sPLA <sub>2</sub> .....	244
3.4. Important precautions .....	245
4. Conclusion .....	246
Acknowledgements .....	247
References .....	247

---

## 1. Introduction

Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) catalyzes the hydrolysis of fatty acids from the *sn*-2 position of phospholipids. The release of fatty acids including arachidonic acid (AA) and lysophospholipids from the cell membrane by PLA<sub>2</sub> activity leads to a cascade of lipid second messengers that regulates a wide variety of physiological responses. Interest in the PLA<sub>2</sub> field has increased in the past decade with the discovery of the important role of lipid messengers in diseases such as cancer [1–3] and atherosclerosis [4,5]. While lipidomics approaches should help elucidate the intricate relationships of the numerous lipid messengers, the ability to also block and measure the activity of the specific PLA<sub>2</sub> enzymes that initiate lipid second messenger release should aid in lipidomics studies.

In 1999, our laboratory published a manuscript on group-specific assays describing four specific PLA<sub>2</sub> assays [6] that were designed to distinguish between the four major mammalian PLA<sub>2</sub> enzymes that had been identified at that time. The assays took advantage of differences in preferred lipid substrate and activators, calcium dependence and susceptibility to disulfide bond reduction to distinguish between the Group IVA cytosolic PLA<sub>2</sub> (GIVA cPLA<sub>2</sub>), the Group VIA calcium-independent PLA<sub>2</sub> (GVIA iPLA<sub>2</sub>) and two secreted sPLA<sub>2</sub>s (GVIA and GV sPLA<sub>2</sub>). The power of these assays lies in their use in determining the activity of each of these enzymes in a biological sample.

In the decade following the research that contributed to the manuscript's preparation, major advances have occurred in the PLA<sub>2</sub> field. Two new paralogs of the GIVA cPLA<sub>2</sub> were

discovered and characterized [7,8] as well as new forms of iPLA<sub>2</sub> [9], and a number of novel sPLA<sub>2</sub> enzymes, bringing the current count to 10 different mammalian sPLA<sub>2</sub>s [9–12]. It should be noted that at this time, 14 groups and numerous subgroups of PLA<sub>2</sub>s have been described [9,13]. These 14 groups include four main “types” of PLA<sub>2</sub>s including sPLA<sub>2</sub>s, cPLA<sub>2</sub>s, iPLA<sub>2</sub>s and PAF-acetyl hydrolases. This manuscript focuses on group-specific assays for a mammalian example of each of the first three types. The fourth type, the PAF-acetyl hydrolase enzymes (Groups VII and VIII), acts on PAF and/or oxidized phospholipids and not on long chain “normal” phospholipids. Thus, the assays described herein should not detect this type of PLA<sub>2</sub>. However, some of the types of enzymes described herein could act on PAF and oxidize phospholipids, so if group-specific assays for PAF-acetyl hydrolases are desired, analogous strategies to those described herein could be devised for PAF-acetyl hydrolases.

Herein, a review and update of the PLA<sub>2</sub> activity assays is provided in light of these recent findings on unique PLA<sub>2</sub>s. Additionally, new information regarding specific inhibitors of the various PLA<sub>2</sub>s has been developed so that we now include inhibitors in the assays that improve the specificity of the assays. Practical tips and technical details are offered for each assay that are hoped to be of use to the PLA<sub>2</sub> novice and expert alike. In addition, we illustrate the usefulness of these assays on a typical biological sample of interest to the neuroscience community, namely rat spinal cord homogenates.

## 2. Materials and methods

### 2.1. Materials

Non-radioactive lipids were purchased from Avanti Polar Lipids: 1-palmitoyl-2-arachidonoyl-diacyl-*sn*-glycero-3-phosphatidylcholine (PAPC), 1-palmitoyl-2-palmitoyl-diacyl-*sn*-glycero-3-phosphatidylcholine (DPPC), 1-palmitoyl-2-linoleoyl-*sn*-glycero-3-phosphatidylethanolamine (PLPE) and 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphatidylserine (POPS). Phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) was purchased from Roche Applied Science. Radioactive PAPC was purchased from Perkin-Elmer Life Sciences: phosphatidylcholine, L- $\alpha$ -1-palmitoyl-2-arachidonoyl and [arachidonoyl-1-<sup>14</sup>C]. Radioactive DPPC and PLPE were purchased from Amersham Biosciences: phosphatidylcholine, 1-palmitoyl-2-[<sup>14</sup>C] palmitoyl and 1-palmitoyl-2-[<sup>14</sup>C] linoleoyl-phosphatidyl ethanolamine. Triton X-100 was purchased from CalBiochem. Bromoenol lactone (BEL) was purchased from Cayman Chemical. Methyl arachidonoyl fluorophosphonate (MAFP) was purchased from Cayman Chemical (shipped in methyl acetate solution) as well as from Biomol (shipped as a dry powder). LY311727 was a kind gift from Lilly Research Laboratories. Indoxam was a gift from Shionogi Research Laboratories.

### 2.2. Phospholipase A<sub>2</sub> enzymes

Synthetic human Group IIA sPLA<sub>2</sub> was a generous gift of Drs. T. Hackeng and J. Griffin at the Research Institute of Scripps Clinic and was chemically synthesized and folded as described [14]. Recombinant human Group V sPLA<sub>2</sub> was expressed, purified and folded in

our laboratory (Six et al., in preparation). The human Group IVA cPLA<sub>2</sub> was a generous gift from Drs. R. Kramer and J. Sharp at Lilly Research Laboratories [15]. The human Group VIA-2 iPLA<sub>2</sub> was expressed and purified in our laboratory (Stevens et al., in preparation).

### 2.3. Preparation of rat spinal cord homogenate and rat cerebral spinal fluid

Prior to sacrifice, the rats were deeply anesthetized and after decapitation, the spinal cords were ejected from the spinal column by a saline-filled syringe. The lumbar part of the spinal cord was frozen on dry ice and stored at  $-70^{\circ}\text{C}$ . Frozen spinal cords were pulverized using a BioPulverizor (Biospec Products) pre-chilled on dry ice. Pulverized tissue was then transferred to a microcentrifuge tube and mixed with 750  $\mu\text{L}$  lysis buffer: 10 mM Hepes, pH 7.5, 1 mM EDTA and 0.34 M sucrose. Twenty microlitres of mammalian protease inhibitor cocktail (Sigma) was added immediately. Samples were vortexed and sonicated until homogenous and then centrifuged at  $16,000 \times g$ ,  $4^{\circ}\text{C}$ , 40 min. Supernatants were transferred to a fresh eppendorf tube and the pellet was discarded.

### 2.4. Phospholipase A<sub>2</sub> assays

#### 2.4.1. Lipid preparation

Lipid was aliquotted, dried under N<sub>2</sub> and lyophilized for at least 1 h to remove all traces of chloroform. For mixed micelles, the lipid was then resuspended in 100 mM Hepes and Triton X-100 and micelles were created by repeated vortexing and heating in hot water until the solution clarified. For small unilamellar vesicles (SUVs), the lipid was resuspended in 100 mM Hepes, vortexed for 10 min and then sonicated on ice until the solution cleared. The preparation was then tested by centrifuging an aliquot at  $15,000 \times g$ , RT for 5 min. The radioactivity of a 5  $\mu\text{L}$  sample of the centrifuged samples as well as a 5  $\mu\text{L}$  sample of the original preparation was determined by scintillation counting and compared. If SUVs do not form properly, they will precipitate upon centrifugation and the respective radioactive counts will be significantly different. Substrate was used only if the counts were within 200 cpm of each other.

#### 2.4.2. Assay conditions

Group IV cPLA<sub>2</sub> assay—100  $\mu\text{M}$  lipid PAPC/PIP<sub>2</sub> (97/3) doping with 100,000 cpm <sup>14</sup>C labeled PAPC in 400  $\mu\text{M}$  Triton X-100 mixed micelles, 100 mM Hepes, pH 7.5, 0.08 mM CaCl<sub>2</sub>, 0.1 mg/mL BSA and 2 mM DTT. Group VI iPLA<sub>2</sub> assay—100  $\mu\text{M}$  DPPC doping with 100,000 cpm <sup>14</sup>C labeled DPPC in 400  $\mu\text{M}$  Triton X-100 mixed micelles, 100 mM Hepes, pH 7.5, 5 mM EDTA and 1 mM ATP. Group V sPLA<sub>2</sub> assay—100  $\mu\text{M}$  DPPC/POPS (3/1) doping with 100,000 cpm <sup>14</sup>C labeled DPPC SUV's, 100 mM Hepes, pH 7.5, 5 mM Ca<sup>2+</sup> and 1 mg/mL BSA. Group IIA sPLA<sub>2</sub> assay—100  $\mu\text{M}$  PLPE/POPS (1/1) doping with 100,000 cpm <sup>14</sup>C labeled PLPE SUVs, 100 mM Hepes, pH 7.5, 1 mM Ca<sup>2+</sup> and 1 mg/mL BSA.

The total volume for each assay is 500  $\mu\text{L}$ —200  $\mu\text{L}$  lipid, 250  $\mu\text{L}$  assay buffer and 50  $\mu\text{L}$  sample. For the biological samples, the amount of calcium or EDTA added was adjusted to account for the addition of EDTA in the lysis buffer to give the final concentrations listed above. Pure enzymes were incubated with substrate for 30 min while biological samples

were incubated with substrate for 1 h at 40 °C in a shaking bath. The assay was then terminated by addition of 2.5 mL Dole Reagent (isopropyl alcohol:heptane:0.5 M sulfuric acid, 400:100:20, v/v/v). Silica gel (0.1–0.2 mg) was added to each tube followed by 1.5 mL heptane and 1.5 mL deionized water. Each tube was vortexed for 15 s. One millilitre of the organic phase was removed and passed through a Pasteur pipet filled with silica gel (0.1–0.2 mg). This column was then washed with 1 mL diethyl ether. Five millilitres of scintillation cocktail (Biosafe II, RPI) was then added to the eluent and the radioactivity was determined by scintillation counting.

#### 2.4.3. Data analysis

Unless otherwise indicated, experiments were performed in at least two independent sets, each in duplicate. A representative experiment is shown. Results are presented as the mean  $\pm$  standard deviation. Differences between groups were compared with one-way ANOVA using Prism statistical software.

### 3. Results and discussion

#### 3.1. Group-specific assays on pure enzymes

The original manuscript in which the group-specific PLA<sub>2</sub> assays were described [6] utilized four PLA<sub>2</sub> enzymes: synthetic human GIIA sPLA<sub>2</sub>, recombinant human GIVA cPLA<sub>2</sub>, recombinant human GV sPLA<sub>2</sub> and GVIA iPLA<sub>2</sub> purified from rat brain. The current manuscript improves on these sources in two ways. First, we have recently developed a method to express and purify recombinant human GVIA-2 iPLA<sub>2</sub> so that we can now test the assays using all purified, human PLA<sub>2</sub> enzymes. Additionally, the GV sPLA<sub>2</sub> that was originally used contained extra, non-native amino acids at the N-terminus. We have now developed a method to express and purify GV sPLA<sub>2</sub> without these extraneous amino acids that shows higher intrinsic activity. Fig. 1 shows a coomassie-stained SDS-PAGE gel of the four enzymes used to retest the assays. The activity of each of these enzymes in the four assays is shown in Fig. 2. Using these purified, human enzymes, the assay results are in good agreement with the original findings.

#### 3.2. Proof of principle: testing a biological sample

While these assays work well to differentiate the activity of pure PLA<sub>2</sub> enzymes, the purpose of their development was to differentiate between mixtures of PLA<sub>2</sub>s found in a biological sample. The specificity of each assay can be tested by observing the effect of the addition of PLA<sub>2</sub> inhibitors on activity. The inhibitors and compounds used to decrease PLA<sub>2</sub> activity in this study are summarized in Table 1.

Rat spinal cord homogenate was chosen as a test material for assay specificity because it is known to express at least one PLA<sub>2</sub> enzyme from each of the three main types of PLA<sub>2</sub> (sPLA<sub>2</sub>, cPLA<sub>2</sub> and iPLA<sub>2</sub>) [16,17]. For each assay, 50  $\mu$ L of rat spinal cord homogenate was incubated with substrate for 1 h in the presence or absence of 0.8 mol% PLA<sub>2</sub> inhibitor, 10 mM DTT or 5 mM EDTA. Only 0.8 mol% inhibitor is added to the substrate because




Fig. 1. Coomassie-stained SDS-PAGE of purified enzymes. (A) Lane 1: molecular weight ladder; lane 2: GIIA sPLA<sub>2</sub>; lane 3: GIVA cPLA<sub>2</sub>. (B) Lane 1: GV sPLA<sub>2</sub>; lane 2: GVIA-2 iPLA<sub>2</sub>; lane 3: molecular weight ladder.




Fig. 2. Group-specific assays tested on purified enzymes. (A) GIVA cPLA<sub>2</sub> specific assay: 100 μM PAPC/PIP<sub>2</sub> (97/3)/400 μM Triton X-100 mixed micelles; (B) GVI iPLA<sub>2</sub> specific assay: 100 μM DPPC/400 μM Triton X-100 mixed micelles, ND indicates activity was not detected; (C) GV sPLA<sub>2</sub> specific assay: 100 μM DPPC/POPS (3/1) SUVs and (D) GIIA sPLA<sub>2</sub> specific assay: 100 μM PLPE/POPS (1/1) SUVs.

Table 1  
PLA<sub>2</sub> inhibitors

Inhibitor/compound	PLA <sub>2</sub> s inhibited	Method of inhibition
MAFP	GIVA, GIVB, GIVC cPLA <sub>2</sub> GVIA iPLA <sub>2</sub>	Enzyme inhibitor
BEL	GVIA, GVIB iPLA <sub>2</sub>	Enzyme inhibitor
LY311727	All sPLA <sub>2</sub> s	Enzyme inhibitor
Indoxam	All sPLA <sub>2</sub> s	Enzyme inhibitor
EDTA	All sPLA <sub>2</sub> s, GIVA, GIVB cPLA <sub>2</sub>	Chelates calcium required for catalysis or binding of the C2 domain
DTT	All sPLA <sub>2</sub> s	Reduces disulfide bonds to denature protein structure

higher concentrations could interfere with the presentation of the substrate, resulting in a non-specific decrease of the activity. As a result of this low inhibitor concentration, complete inhibition of activity is not expected. The results of these assays are presented in Figs. 3 and 4 and are discussed below.




Fig. 3. PLA<sub>2</sub> activity of rat spinal cord homogenate on the GIVA cPLA<sub>2</sub> and GVI iPLA<sub>2</sub> specific assays,  $n = 3$ . Samples are tested on substrate alone (control) or in the presence of 0.8 mol% PLA<sub>2</sub> inhibitor (MAFP, BEL or LY311727). (A) GIVA cPLA<sub>2</sub> specific assay: 100  $\mu$ M PAPC/PIP<sub>2</sub> (97/3)/400  $\mu$ M Triton X-100 mixed micelles, (B) GVI iPLA<sub>2</sub> specific assay: 100  $\mu$ M DPPC/400  $\mu$ M Triton X-100 mixed micelles. \* $P < 0.001$  compared with control. Portions of this figure are reprinted with permission from the *British Journal of Pharmacology* [27].




Fig. 4. PLA<sub>2</sub> activity of rat spinal cord homogenate tested on the sPLA<sub>2</sub> specific assays,  $n = 3$ . Samples are tested on substrate alone (control) or in the presence of 0.8 mol% PLA<sub>2</sub> inhibitor (MAFP, BEL, LY311727 or Indoxam), or in the presence of reducing agent (10 mM DTT) or a cation chelator (5 mM EDTA). (A) GV sPLA<sub>2</sub> specific assay: 100  $\mu$ M DPPC/POPS (3/1) SUVs, (B) GIIA sPLA<sub>2</sub> specific assay: 100  $\mu$ M PLPE/POPS (1/1) SUVs. \* $P < 0.001$ , \*\* $P < 0.05$ , compared with control. Portions of this figure are reprinted with permission from *Neuroscience* [17].

### 3.3. Specificity improved assays

The results obtained from this study demonstrate the advantage of adding inhibitors to the assays to improve their specificity for use in testing biological samples. This can be accomplished by the addition of specific PLA<sub>2</sub> inhibitors to the assay buffers. However, even with these improvements, it is strongly recommended that researchers verify the specificity of these assays for each biological sample type to be tested. Table 2 summarizes the substrate and buffer conditions of each assay as well as compounds that can be used to inhibit the activity of that PLA<sub>2</sub> subgroup. For each assay, it is recommended that the specificity be verified both by inhibiting the activity of interest (for example, decreasing GIVA cPLA<sub>2</sub> activity with MAFP) as well as by excluding the possibility of crossover from other PLA<sub>2</sub>s (for example, also testing for iPLA<sub>2</sub> activity with BEL and sPLA<sub>2</sub> activity with DTT). The principles, improvements and specificity of each of these assays are discussed below.

#### 3.3.1. GIVA cPLA<sub>2</sub>

The GIVA cPLA<sub>2</sub> assay takes advantage of the enzymes known preference for arachidonic acid at the *sn*-2 position of phospholipid [18] as well as its demonstrated ~100-fold increase in activity in the presence of PIP<sub>2</sub> in a Triton X-100 mixed micelle substrate [19]. The buffer includes 80 μM Ca<sup>2+</sup>, which is enough for GIVA cPLA<sub>2</sub> to be active but not the sPLA<sub>2</sub>s, as well as 2 mM DTT, which acts to reduce the disulfide bonds of the sPLA<sub>2</sub>s to denature these enzymes. The two sPLA<sub>2</sub>s tested had negligible activity in this assay, but as was found previously, GVIA-2 iPLA<sub>2</sub> does have measurable, although low activity (Fig. 2A). These findings are further supported by the results of the biological sample testing (Fig. 3A). The activity of rat spinal cord homogenate in the GIVA cPLA<sub>2</sub> assay was almost entirely inhibited by MAFP, a widely used iPLA<sub>2</sub> and cPLA<sub>2</sub> inhibitor [20], while the sPLA<sub>2</sub> inhibitor, LY311727, had no effect. The Group VI iPLA<sub>2</sub> inhibitor, BEL, reduced the activity slightly, demonstrating the GVI iPLA<sub>2</sub> crossover in the assay, although this decrease was not statistically significant.

The original manuscript [6] describes a mathematical method to subtract the GVI iPLA<sub>2</sub> activity from the total activity to determine the contribution specific to GIVA cPLA<sub>2</sub>. This method has two major disadvantages. First, it requires that biological samples be assayed

Table 2  
Inhibitor-based PLA<sub>2</sub> assays and tests for specificity

PLA <sub>2</sub> class	cPLA <sub>2</sub>	iPLA <sub>2</sub>	sPLA <sub>2</sub>
Substrate	100 μM PAPC/PIP <sub>2</sub> (97/3), 400 μM Triton X-100 mixed micelles	100 μM DPPC, 400 μM Triton X-100 mixed micelles	100 μM PLPE/POPS (1/1) SUVs (or 100 μM DPPC/POPS (3/1) SUVs)
Buffer conditions	100 mM Hepes, 0.08 mM CaCl <sub>2</sub> , 0.1 mg/mL BSA, 2 mM DTT, 0.8 μM BEL	100 mM Hepes, 5 mM EDTA, 1 mM ATP, 2 mM DTT	100 mM Hepes, 1 (or 5)mM CaCl <sub>2</sub> , 1 mg/mL BSA, 0.8 μM MAFP
Test compounds	MAFP, EDTA	MAFP, BEL	EDTA, DTT, indoxam, LY311727



both for cPLA<sub>2</sub> as well as iPLA<sub>2</sub> activity even if only the cPLA<sub>2</sub> activity is of interest. Secondly, it assumes that the specific activity of the GVI iPLA<sub>2</sub> is constant. Because there may be significant differences in the specific activities of the GVI iPLA<sub>2</sub> splice variants as well as species differences between orthologs, this is a risky assumption. We instead suggest including 0.8 mol% bromoenol lactone in the cPLA<sub>2</sub> assay to eliminate any iPLA<sub>2</sub> crossover. BEL specifically inhibits the GVI iPLA<sub>2</sub>, but does not inhibit any of the GIV cPLA<sub>2</sub> paralogs [21]. It should be noted that while BEL is specific for iPLA<sub>2</sub> within the PLA<sub>2</sub> family, it is also known to potently inhibit phosphatidic acid phosphohydrolase (PAP-1) [22].

As was mentioned in Section 1, two novel cPLA<sub>2</sub> paralogs have recently been described. Neither GIVB nor GIVC cPLA<sub>2</sub> are activated by PIP<sub>2</sub> [21]; therefore, these enzymes should have negligible activity in this assay. Furthermore, GIVB cPLA<sub>2</sub> has very low intrinsic activity so that a vast quantity would have to be present in a sample to produce any appreciable activity in this assay. However, it should be noted that it is not possible to rule out the contribution of GIVB activity to this assay with absolute certainty.

To verify that GIVC cPLA<sub>2</sub> is not contributing to the activity, a biological sample can be tested in the presence of BEL and EDTA. Because GIVC cPLA<sub>2</sub> has no calcium dependence and is not inhibited by BEL, it is the only known PLA<sub>2</sub> that will have catalytic activity under these conditions. If activity is found, it can be subtracted from the activity of the Group IVA cPLA<sub>2</sub> assay to determine the GIVA contribution. Recently, a pyrrolidine-based molecule has been reported to inhibit GIVA cPLA<sub>2</sub> activity while having significantly less inhibitory action against GIVC cPLA<sub>2</sub> that might be used to distinguish the two activities [23]. Unfortunately, this inhibitor is not commercially available.

### 3.3.2. GVI iPLA<sub>2</sub>

The iPLA<sub>2</sub> assay is the most specific of the four assays. None of the other purified enzymes had any activity in this assay (Fig. 2B) and the rat spinal cord homogenate activity in this assay was inhibited by BEL and MAFP but not LY311727 (Fig. 3B). The assays specificity can be attributed to the 5 mM EDTA in the assay buffer that acts as a calcium chelator. All sPLA<sub>2</sub>s tested thus far have an absolute calcium requirement for catalysis. The GIVA and GIVB cPLA<sub>2</sub> both have a C2 domain that sequesters the enzymes to the membrane upon calcium binding. However, there is one other PLA<sub>2</sub> enzyme in addition to the iPLA<sub>2</sub> subfamily that is calcium independent, Group IVC cPLA<sub>2</sub>. In initial experiments utilizing cell lysates overexpressing GIVC cPLA<sub>2</sub>, this enzyme has been found to have significant activity in the iPLA<sub>2</sub> assay (unpublished observations). Therefore, it is possible that GIVC cPLA<sub>2</sub> can contribute to the activity in this assay if it is present in a biological sample. To rule out any contribution by this PLA<sub>2</sub> subtype, the sample can be assayed with and without the addition of up to 2 mol% BEL, which will specifically inhibit GVI iPLA<sub>2</sub> activity but not GIVC cPLA<sub>2</sub>. If significant activity remains in the presence of BEL, it is likely due to GIVC cPLA<sub>2</sub>. Unfortunately, a compound has not yet been found which inhibits GIVC cPLA<sub>2</sub> but not GVI iPLA<sub>2</sub>. However, by performing the assay both with and without BEL, the contribution to the observed activity from GIVC cPLA<sub>2</sub> can be determined and then subtracted from the total activity.

### 3.3.3. sPLA<sub>2</sub>

At the time the original group-specific assay manuscript [6] was written, the two major sPLA<sub>2</sub> enzymes found in biological samples were Groups IIA and V. The authors developed an assay for each of these enzymes that would distinguish one from the other as well as from the GVI iPLA<sub>2</sub> and GIVA cPLA<sub>2</sub>. These assays maintained their specificity when tested with purified, human PLA<sub>2</sub>s (Fig. 2C and D). The original manuscript [6] describes a mathematical method to subtract the GV sPLA<sub>2</sub> activity from the GIIA assay and vice versa in order to determine the true GIIA and GV sPLA<sub>2</sub> activity in a biological sample. Today, 10 different mammalian sPLA<sub>2</sub>s have been identified and as their activity under these conditions is unknown, this simple mathematical subtraction is no longer valid nor is the specification as “Group IIA” or “Group V” assay. Rather, both of these assays should be regarded as general sPLA<sub>2</sub> assays. For ease of discussion, these historical distinctions will be adhered to in this manuscript.

Both of these sPLA<sub>2</sub> assays proved to be less specific when used to assay the spinal cord homogenate. The “GV” sPLA<sub>2</sub> assay, which uses DPPC/POPS (3/1) as its substrate, did not show a decrease in activity with the addition of BEL, LY311727 or indoxam, but was decreased somewhat by MAFP (Fig. 4A). Addition of EDTA or pre-incubation of the spinal cord homogenate for 30 min with 10 mM DTT also failed to decrease the observed activity (Fig. 4A), indicating that the observed activity cannot be attributed to any sPLA<sub>2</sub>.

The rat spinal cord homogenate activity in the “GIIA” sPLA<sub>2</sub> assay, which uses PLPE/POPS (1/1) as its substrate, was decreased by all three PLA<sub>2</sub> inhibitors (Fig. 4B). In addition, DTT and EDTA only partially decreased the activity. This evidence indicates that in the presence of a biological sample, the GIIA assay is no longer sPLA<sub>2</sub> specific and in fact presents substrate that can be hydrolyzed by all three PLA<sub>2</sub> classes. This change is likely due to the presence of phospholipid from the spinal cord homogenate, which alters the presentation of the phospholipid substrate. Even after centrifugation, some phospholipid will remain in the supernatant of most biological samples. It is important to recognize the ability of phospholipid from the biological sample to interact with the phospholipid substrate of the assay and to limit the addition of physiological phospholipid as much as possible. In addition to altering the specificity of the assay, phospholipid addition can also result in an apparent reduction in activity because the ratio of radioactive lipid to non-labeled lipid will decrease resulting in the release of less radiolabel due to surface dilution.

The GIIA sPLA<sub>2</sub> assay can be modified by the addition of 0.8 mol% MAFP to restore its sPLA<sub>2</sub> selectivity. The addition of MAFP will act to inhibit all of the GIV cPLA<sub>2</sub> paralogs as well as any GVI iPLA<sub>2</sub> activity. The remaining activity can thus be confidently attributed to sPLA<sub>2</sub>. The suitability of this assay was demonstrated by testing rat spinal cord homogenate in the presence of substrate alone, in the presence of either MAFP or LY311727, or in the presence of both MAFP and LY311727 (at 0.8 mol% each) (Fig. 5). When combined, the inhibitors had an additive effect, thereby demonstrating that the PLA<sub>2</sub> activity is indeed attributable to multiple enzymes and verifying that the addition of MAFP results in the measurement of only sPLA<sub>2</sub> activity.

A number of recent publications have utilized indoxam, a novel, potent inhibitor of sPLA<sub>2</sub> to successfully decrease sPLA<sub>2</sub> activity [24–26]. Although indoxam is not sold commercially at this time, it may be used to distinguish sPLA<sub>2</sub> activity if it is available.




Fig. 5. PLA<sub>2</sub> activity of rat spinal cord homogenate on the GIIA sPLA<sub>2</sub> specific assay,  $n=9$ . Samples are tested on substrate alone (control) or in the presence of 0.8 mol% PLA<sub>2</sub> inhibitor (MAFP, LY311727, LY311727 + MAFP at 0.8 mol% each). \* $P < 0.001$ , \*\* $P < 0.05$  compared with control. Portions of this figure are reprinted with permission from *Neuroscience* [17].

### 3.4. Important precautions

When testing the sPLA<sub>2</sub> activity of a biological sample, special precaution should be taken to avoid any blood contamination as blood contains a high level of GIIA sPLA<sub>2</sub>. We found a very substantial amount of sPLA<sub>2</sub> activity in rat cerebral spinal fluid which was highly sensitive to LY311727 only to determine later that it was due entirely to blood contamination. When the samples were cleanly removed from the animal, we found no sPLA<sub>2</sub> activity at all (Fig. 6).

Much of the specificity of these assays is established by the concentration of calcium. It is very important to achieve the final calcium concentrations listed in Table 2. Many lysis buffers and most protease inhibitor cocktails include significant concentrations of EDTA or EGTA, which will chelate the calcium in the assay. It is of vital importance to compensate for this chelation with the addition of equimolar calcium to the assay. Endogenous calcium




Fig. 6. PLA<sub>2</sub> activity of rat cerebral spinal fluid on the GIIA sPLA<sub>2</sub> specific assay. Samples contaminated with blood demonstrated significant activity (control,  $n=2$ ) that was inhibited by LY311727 ( $n=2$ ). Samples that were not contaminated with blood did not have significant activity ( $n=25$ ).




Fig. 7. MAFP inhibition profile. Purified enzymes were tested on substrate alone (control) or in the presence of 0.8 mol% inhibitor (oxidized MAFP or Cayman MAFP). \* $P < 0.001$ , \*\* $P < 0.05$  compared with control.

from the biological sample has not interfered with any of these assays in studies performed thus far.

Reproducibility is also an important issue of which to be aware. Even the most experienced phospholipid chemist is hard pressed to prepare substrate on two different days, which will produce the same specific activity for a given sample. We have found that the activity of biological samples can vary up to 5-fold from substrate preparation to preparation. The best way to compare the PLA<sub>2</sub> activity in a number of biological samples is to test all the samples on the same day using the same substrate. If this is not possible, an internal standard of pure PLA<sub>2</sub> enzyme may be used to adjust for the variation in phospholipid preparations.

Finally, a special precaution must be mentioned regarding the source of the PLA<sub>2</sub> inhibitor MAFP. During our studies, we tested two sources of MAFP, one was shipped as a dry powder while the other was shipped in a solution of methyl acetate. Both inhibitors were tested on the pure enzymes and it was discovered that the MAFP that had been shipped dry had the exact opposite inhibition profile than was expected. These samples of MAFP inhibited the activity of the GIIA and GV sPLA<sub>2</sub>s but not GIVA cPLA<sub>2</sub>. NMR analysis of these samples indicated that the MAFP that had been shipped dry was highly oxidized (data not shown). Cayman chemical ships MAFP in a methyl acetate solution and this preparation exhibits the expected inhibition profile (Fig. 7). Because few researchers test the specificity of commercial inhibitors, this finding is especially alarming and could bring into question the conclusions of many published reports that utilized this source of MAFP.

#### 4. Conclusion

As interest in the inflammatory component of disease increases, so will the desire to elucidate the role different PLA<sub>2</sub> types play in the initiation of the inflammatory response. This update establishes the utility of the PLA<sub>2</sub> group-specific assays in light of new developments in the PLA<sub>2</sub> field and is hoped to be of use to the research community.

## Acknowledgements

This research was supported by funding from the National Institute of Health, GM 64611 and GM 20501. The authors wish to thank Camilla Svensson and Tony L. Yaksh for providing the rat spinal cord samples.

## References

- [1] Laye JP, Gill JH. Phospholipase A<sub>2</sub> expression in tumours: a target for therapeutic intervention? *Drug Discov Today* 2003;8:710.
- [2] Ohshima H, Tatemichi M, Sawa T. Chemical basis of inflammation-induced carcinogenesis. *Arch Biochem Biophys* 2003;417:3.
- [3] van Golen KL. Inflammatory breast cancer: relationship between growth factor signaling and motility in aggressive cancers. *Breast Cancer Res* 2003;5:174.
- [4] Libby P. Inflammation in atherosclerosis. *Nature* 2002;420:868.
- [5] Rajala MW, Scherer PE. Minireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. *Endocrinology* 2003;144:3765.
- [6] Yang HC, Mosior M, Johnson CA, Chen Y, Dennis EA. Group-specific assays that distinguish between the four major types of mammalian phospholipase A<sub>2</sub>. *Anal Biochem* 1999;269:278.
- [7] Pickard RT, Striffler BA, Kramer RM, Sharp JD. Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A<sub>2</sub>. *J Biol Chem* 1999;274:8823.
- [8] Underwood KW, Song C, Kriz RW, Chang XJ, Knopf JL, Lin LL. A novel calcium-independent phospholipase A<sub>2</sub>, cPLA<sub>2</sub>-gamma, that is prenylated and contains homology to cPLA<sub>2</sub>. *J Biol Chem* 1998;273:21926.
- [9] Six DA, Dennis EA. The expanding superfamily of phospholipase A<sub>2</sub> enzymes: classification and characterization. *Biochim Biophys Acta (BBA) Mol Cell Biol Lipids* 2000;1488:1.
- [10] Balsinde J, Barbour SE, Bianco ID, Dennis EA. Arachidonic acid mobilization in P388D<sub>1</sub> macrophages is controlled by two distinct Ca<sup>2+</sup>-dependent phospholipase A<sub>2</sub> enzymes. *Proc Natl Acad Sci USA* 1994;91:11060.
- [11] Gelb MH, Valentin E, Ghomashchi F, Lazdunski M, Lambeau G. Cloning and recombinant expression of a structurally novel human secreted phospholipase A<sub>2</sub>. *J Biol Chem* 2000;275:39823.
- [12] Ho IC, Arm JP, Bingham III CO, Choi A, Austen KF, Glimcher LH. A novel group of phospholipase A<sub>2</sub>s preferentially expressed in type 2 helper T cells. *J Biol Chem* 2001;276:18321.
- [13] Balsinde J, Winstead MV, Dennis EA. Phospholipase A<sub>2</sub> regulation of arachidonic acid mobilization. *FEBS Lett* 2002;531:2.
- [14] Hackeng TM, Mounier CM, Bon C, Dawson PE, Griffin JH, Kent SB. Total chemical synthesis of enzymatically active human type II secretory phospholipase A<sub>2</sub>. *Proc Natl Acad Sci USA* 1997;94:7845.
- [15] Sharp JD, White DL, Chiou XG, et al. Molecular cloning and expression of human Ca<sup>2+</sup>-sensitive cytosolic phospholipase A<sub>2</sub>. *J Biol Chem* 1991;266:14850.
- [16] Lucas KK, Svensson CI, Yaksh TL, Dennis EA. The novel contribution of spinal phospholipase A<sub>2</sub> to inflammatory hyperalgesia. In: *Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation and Related Diseases*, 8th International Conference; 2003 [Abstract].
- [17] Svensson CI, Luca KK, Hua XY, Powell HC, Dennis EA, Yaksh TL. Spinal phospholipase A<sub>2</sub> in inflammatory hyperalgesia: role of the small, secreted sPLA<sub>2</sub>s. *Neuroscience* 2005, in press.
- [18] Diez E, Louis-Flamberg P, Hall RH, Mayer RJ. Substrate specificities and properties of human phospholipases A<sub>2</sub> in a mixed vesicle model. *J Biol Chem* 1992;267:18342.
- [19] Mosior M, Six DA, Dennis EA. Group IV cytosolic phospholipase A<sub>2</sub> binds with high affinity and specificity to phosphatidylinositol 4,5-bisphosphate resulting in dramatic increases in activity. *J Biol Chem* 1998;273:2184.
- [20] Ghomashchi F, Loo R, Balsinde J, et al. Trifluoromethyl ketones and methyl fluorophosphonates as inhibitors of group IV and VI phospholipases A<sub>2</sub>: structure-function studies with vesicle, micelle, and membrane assays. *Biochim Biophys Acta (BBA) Biomembr* 1999;1420:45.
- [21] Lucas KK, Dennis EA. The ABC's of Group IV cytosolic phospholipase A<sub>2</sub>. *Biochem Biophys Acta* 2004;1636:213.

- [22] Balsinde J, Dennis EA. Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D<sub>1</sub> macrophages. *J Biol Chem* 1996;271:31937.
- [23] Ghomashchi F, Stewart A, Hefner Y, et al. A pyrrolidine-based specific inhibitor of cytosolic phospholipase A<sub>2</sub> blocks arachidonic acid release in a variety of mammalian cells. *Biochim Biophys Acta (BBA) Biomembr* 2001;1513:160.
- [24] Degousee N, Ghomashchi F, Stefanski E, et al. Groups IV, V, and X phospholipases A<sub>2</sub>s in human neutrophils. Role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. *J Biol Chem* 2002;277:5061.
- [25] Beck S, Lambeau G, Scholz-Pedretti K, et al. Potentiation of tumor necrosis factor-induced secreted phospholipase A<sub>2</sub> (sPLA<sub>2</sub>)-IIA expression in mesangial cells by an autocrine loop involving sPLA<sub>2</sub> and peroxisome proliferator-activated receptor activation. *J Biol Chem* 2003;278:29799.
- [26] Mounier CM, Ghomashchi F, Lindsay MR, et al. Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A<sub>2</sub> occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A<sub>2</sub>. *J Biol Chem* 2004;279:25038.
- [27] Lucas KK, Svensson CI, Hua XY, Yaksh TL, Dennis EA. Spinal phospholipase A<sub>2</sub> in inflammatory hyperalgesia: role of Group IVA cPLA<sub>2</sub>. *Br J Pharmacol* 2005;144:940.